NovaBay Establishes Primary Proof of Concept for NVC-422 Phase 2 UCBE Clinical Program – Yahoo Finance

Nov. 30, 2011 (GLOBE NEWSWIRE) — NovaBay (R) Pharmaceuticals, Inc. (NYSE AMEX:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide (R) compounds for the local non-systemic treatment and prevention …